Interestingly, patients with low HLA-B HED tended to exhibit higher TP53 mutational frequencies, and patients with TP53 mutated cancers experienced unfavorable clinical outcomes than patients within the wildtype subgroup. The gene discussed is TP53; the disease is cancer.